Earnings call transcript: BONESUPPORT jumps on q3 growth, reimbursement boost

BONESUPPORT’s Q3 2026 net sales rose 39% to SEK 409 million, with adjusted operating profit of SEK 139 million and a 34% adjusted margin; full-year sales growth guidance was maintained at 33%–36% in constant currencies. Shares gained 16.33% in pre-market trading to $299.20. The quarter also featured the SOLARIO study, which found short-course systemic antibiotics non-inferior to longer treatment when local antibiotics were used, and a U.S. CMS reimbursement ruling that management expects to support growth over time, though not materially affect Q4 revenue.

Analysis

The key upside is a reduction in hospital adoption friction, not an immediate reimbursement-driven revenue step-up. The inpatient-only CMS change may improve the hospital’s economics and give BONEX’s commercial team a stronger case with administrators, but coding, staff education and hospital purchasing cycles make uptake a multi-quarter conversion funnel. It does not establish higher pricing or guarantee broader use; monitor adoption by inpatient accounts and utilization, not just surgeon interest.

The clinical read-through is also less company-specific than the market may infer. SOLARIO supports local antibiotic therapy as a class and included multiple products; it does not demonstrate CERAMENT superiority. Wider protocol adoption could expand the category while benefiting competitors too. The more BONEX-specific catalysts are execution under the reimbursement codes and FDA action on CERAMENT V. V could add reach, but management’s incremental-growth expectation is unproven and should be tested against post-launch product mix and G utilization.

Near term, the sharp repricing risks outrunning evidence: management explicitly cautioned against treating one quarter’s U.S. acceleration as a new run rate, kept full-year guidance unchanged, and expects no material Q4 CMS contribution. Over 1–3 months, watch guidance delivery, inpatient account conversion and FDA timing; over 6–18 months, sustained adoption and V approval could support the growth case. Margin quality deserves scrutiny: manufacturing costs have pressured gross margin while commercial spending remains elevated. A reversal would be sequential growth deceleration, guidance reduction, delayed FDA action, or no observable uptake despite the reimbursement rollout. The contrarian risk is that the market capitalizes class-level clinical evidence and a policy tailwind as BONEX-specific economics before either is proven.

Key Decisions for Investors

• Do not chase the pre-market surge. Keep BONEX on a catalyst watch and reassess after the next quarter’s constant-currency growth, inpatient adoption evidence and CMS-code implementation; a guidance cut or clear deceleration would falsify the bullish execution case.
• For existing BONEX exposure, consider trimming into strength rather than underwriting Q4 reimbursement upside. The company says the benefit is expected to build over time, and its maintained annual outlook leaves limited evidence that the exceptional Q3 pace is durable.
• Track CERAMENT V FDA action and post-launch mix before assigning incremental growth value. Verify whether V expands eligible use or substitutes for G; material cannibalization or a delayed FDA response weakens the bull case.
• Treat SYK’s Australia/New Zealand distribution role as optionality, not a near-term earnings catalyst: the reported initial stocking orders are not evidence of a recurring sales run rate.